ESC 365 - Extended, standard or de-escalation antiplatelet therapy after ACS?

ACVC Premium Access

Extended, standard or de-escalation antiplatelet therapy after ACS?

Session: Anti-thrombotic management in patients with acute coronary syndromes (ACS)

Topic: Thrombosis, Platelets, and Coagulation

Speaker: Professor K. Huber (Vienna, AT)

Event: ESC Acute CardioVascular Care 2022

Congress Presentation

About the speaker

Professor Kurt Huber

Wilhelminen Hospital, Vienna (Austria)

42 presentations

9 followers

4 more presentations in this session

The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction

Speaker: Mr S. Rikken (Nieuwegein, NL)

Antiplatelet pretreatment in NSTE-ACS: do we have the answer?

Speaker: Doctor P. Capranzano (Catania, IT)

Do we really need aspirin?

Speaker: Professor R. Mehran (New York, US)

Anti-thrombotic management in patients with acute coronary syndromes - discussion.

Access the full session

Anti-thrombotic management in patients with acute coronary syndromes (ACS)

Speakers: Professor K. Huber, Mr S. Rikken, Doctor P. Capranzano, Professor R. Mehran

About the event

ESC Acute CardioVascular Care 2022

18 March - 19 March 2022

Sessions Presentations

Congress

Related content

ESC Premium Access

DAPT in NSTE-ACS: what, when and for how long?

28 August 2021

Open Access

Panel discussion with audience Q&A.

27 August 2021

ESC Premium Access

Major arterial and venous thromboembolic complications in patients with covid-19

27 August 2021

ESC 365 is supported by